文献速递神经肿瘤

胶质母细胞瘤免疫检查点抑制剂疗效的分子与临床决定因素

Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma.
PubMed 文献 · J Neurooncol · 2025-06-25

该回顾性研究纳入35例复发胶质母细胞瘤接受免疫检查点抑制剂治疗的患者,分析分子、临床与人口学特征与生存结局的关联。结果显示PIK3CA突变、RB1和TERT启动子突变、基线使用类固醇及多灶性疾病与较差疗效相关,而CPI治疗超过6个月可能改善生存。

要点

  • PIK3CA突变与从CPI起始计算的更短总生存显著相关(p=0.014)。
  • 基线使用类固醇与更短总生存相关(p=0.0016),多灶性疾病与更短PFS和OS相关。
  • CPI治疗超过6个月与PFS和OS改善趋势相关(p=0.069、0.088)。

核心结论

  • 在胶质母细胞瘤中,PIK3CA、RB1、TERT启动子突变、CPI开始前使用类固醇及多灶性疾病可能与CPI反应不佳相关,而延长CPI治疗可能改善反应。

研究设计与样本

  • 回顾性研究,纳入35例接受CPI治疗的复发胶质母细胞瘤患者,分析分子、临床和人口学特征与生存结局的关联。

主要发现

  • PIK3CA突变与从CPI起始计算的更短OS显著相关(p=0.014),无该突变的肿瘤组织CD3+/CD8+ T细胞中PD-1表达更少。
  • RB1和TERT启动子突变与更短PFS相关(p=0.009、0.053)。
  • CPI治疗超过6个月与PFS和OS增加相关(p=0.069、0.088)。
  • 基线使用类固醇与更短OS相关(p=0.0016)。
  • 多灶性疾病与所有患者更短PFS和OS相关(p=0.0011、0.0015)。

临床怎么用

  • 对复发胶质母细胞瘤患者启动CPI前,应评估PIK3CA、RB1、TERT启动子突变状态及是否使用类固醇、是否存在多灶性疾病。
  • 上述因素可能提示CPI反应较差,可考虑用于临床决策及临床试验分层。
  • 研究结果提示可开展PI3K抑制剂联合CPI治疗胶质母细胞瘤的临床试验。

局限性

  • 样本量小(35例)。
  • 回顾性研究设计,存在选择偏倚和/或混杂效应。
  • 需要更大规模研究验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While checkpoint inhibitor therapy (CPI) has transformed treatment in multiple solid tumors, its efficacy in glioblastoma (GBM) remains limited. Understanding the molecular and clinical factors that influence glioblastoma's response to CPI is essential to improving outcomes. METHODS: We identified patients with recurrent GBM, who had been treated with CPI and determined the association between their molecular, clinical, and demographic characteristics and survival outcomes. RESULTS: We identified 35 patients with recurrent GBM treated with CPI. PIK3CA mutation was associated with a statistically significant shorter OS duration, calculated from CPI initiation (p-value = 0.014). Tumor tissue without the mutation had less PD-1 expression in CD3+/CD8 + T cells. RB1 and TERT promoter mutations were associated with shorter PFS durations (p-value = 0.009, 0.053, respectively). Length of CPI therapy of more than 6 months was associated with increased PFS and OS (p-value = 0.069, 0.088, respectively), while steroid use at baseline was associated with a shorter OS (p-value = 0.0016). Multifocal disease was associated with shorter PFS and OS durations (p-value = 0.0011, 0.0015, respectively) among all patients. CONCLUSIONS: In glioblastoma, PIK3CA, RB1, TERT promoter mutations, steroid use prior to start of CPI, and multifocal disease may be associated with a poor response to CPI while increased length of CPI may be associated with improved response. Our results may provide the rationale for clinical trials combining PI3K inhibitors with CPI in glioblastoma. The small sample size and retrospective nature of the study carries selection bias and/or confounding effects and larger studies need to be done to validate these results.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Dasgupta P, Lin H, Kumar G, et al. Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma. J Neurooncol. 2025. PMID: 40560330. doi:10.1007/s11060-025-05131-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。